Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Successful treatment of exacerbation: number of participants cured. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants cured.… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Successful treatment of exacerbation: number of participants with P aeruginosa eradication. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes successful treatment of exacerbation: number of participants with P… compared with oral monotherapy (very low certainty).
1 finding from 1 review
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Relapse · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Microbiological response: eradicated. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Hospital admissions · bronchiectasis
1 finding from 1 review
Death · bronchiectasis
1 finding from 1 review
Quality of life · bronchiectasis
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Usual care may leads to lower relapse at 12, 18 or 24 months compared with immunosuppressive withdrawal after monotherapy (low certainty).
1 finding from 1 review
New CD‐related complications · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes new CD‐related complications compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after monotherapy (low certainty).
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
1 finding from 1 review
Clinical cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes clinical cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Mycological cure · participants with confirmed toenail onychomycosis
It is very uncertain whether combination terbinafine plus azole changes mycological cure compared with terbinafine monotherapy (very low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review